The testosterone patch, brand name Intrinsa among others, was designed to treat female sexual dysfunction.
Testosterone therapy is systemic and needs to be applied over a period of weeks or months to have an effect.
[1] The patch was granted a license from the European Medicines Agency in July, and is available on Britain's National Health Service from March 2007.
[citation needed] However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use.
In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months.